Target intelligence / Profile preview

Neuronal ganglioside

Molecular classification
Glycosphingolipid, Glycolipid, Toxin receptor
01

Overview

Neuronal gangliosides are sialic acid-containing glycosphingolipids that are highly enriched in the outer leaflet of neuronal membranes, particularly at the presynaptic terminals of cholinergic neurons (Schengrund, 2015). They function as essential components of the dual-receptor mechanism for clostridial neurotoxins, such as Botulinum neurotoxin (BoNT) and Tetanus neurotoxin (TeNT) (Rummel, 2016). In this mechanism, the toxin's heavy chain first binds to gangliosides like GT1b or GD1a, which anchors the toxin to the membrane and facilitates its subsequent binding to high-affinity protein receptors like Synaptotagmin or SV2 (Dong et al., 2003). This interaction is a prerequisite for the endocytosis of the toxin and the subsequent cleavage of SNARE proteins, which inhibits acetylcholine release and leads to flaccid paralysis (Pirazzini et al., 2017). Beyond their role as toxin receptors, gangliosides are involved in modulating ion channels, cell signaling, and maintaining the stability of lipid rafts (Willison & Yuki, 2002). They are also clinically significant as targets for autoantibodies in autoimmune peripheral neuropathies, such as Guillain-Barré and Miller Fisher syndromes (Yuki & Hartung, 2012).

Other names
GangliosideSialic acid-containing glycosphingolipidGT1bGD1aGM1GD1bGQ1b
02

Mechanism of action

Neuronal gangliosides serve as the initial binding site for clostridial neurotoxins (dual-receptor model), where they concentrate the toxin on the presynaptic membrane to facilitate binding to high-affinity protein receptors (e.g., SV2 or synaptotagmin) for internalization (Rummel, 2016).

03

Biological functions

Toxin binding and internalizationModulation of synaptic transmissionCell-cell recognitionSignal transductionMembrane organization and lipid raft stability
04

Disease associations

BotulismTetanusGuillain-Barré syndromeMiller Fisher syndromeNeurodegenerative disease
05

Safety considerations

Autoimmune cross-reactivity leading to neuropathySystemic botulismIatrogenic botulismImmunogenicity and neutralizing antibody formation
06

Interacting drugs

OnabotulinumtoxinA

5 more in the full profile.

07

Biomarkers

Anti-GQ1b antibodyAnti-GM1 antibodyAnti-GD1a antibodyAnti-GD1b antibody

Beyond the preview

Go deeper on Neuronal ganglioside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronal ganglioside.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call